Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As of yesterday
None of the offering has been issued.
Wow!!!!!
Drugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough.
Bristol Myers Squibb, AstraZeneca, Eli Lilly and other pharmaceutical companies have spent some $10 billion on deals to acquire or work with radiopharmaceutical makers. They’ve snapped up smaller upstarts to get their hands on technology that, while in its infancy, could treat numerous cancers.
“Any large company that has a business presence in oncology or for whom oncology is an important therapeutic category will probably need exposure in this area one way or another,” said Guggenheim Securities analyst Michael Schmidt.
Two radiopharmaceuticals from Novartis are already available. Another few dozen are in development, according to Schmidt’s count. It’s hard to estimate the total market opportunity because there are so many possible cancers the drugs could treat, he said.
https://www.cnbc.com/2024/09/16/radiopharmaceuticals-race-heats-up-as-drugmakers-chase-novartis.html
One thing I learned with this stock.
NEVER expect any disclosed timeline to be shortened. 🙃
The Company anticipates using the proceeds from the July 2024 Regulation A+ Offering as follows:
For the animal therapy market:
? Expand communication on our website, the social media, conference, and journals to increase the number of certified clinics for small animal and equine therapy and to increase the number of patients.
? Subsidize some IsoPet® therapies, if necessary, to ensure that all viable candidates are treated.
? Assist a new regional clinic with their license and certification training.
For the human market:
? Enhance the pedigree of the Quality Management System.
? Begin automation of product manufacturing.
? Fund liability insurance for human clinical studies.
? Fund human clinical studies in the US.
You are mistaken.
BDD does not change the IDE Approval Timeline of 30 days.
We're good either way, we will have approval by Halloween!
MK Buys More....
https://www.sec.gov/Archives/edgar/data/1449349/000141588924020862/xslF345X05/form4-08072024_050829.xml
Common Stock 08/07/2024 Purchase 50,000 At $0.1176
Today is tomorrow in Japan
Of course they are!
$2 billion technology with under 500M shares
I like those numbers...
THE END
$RDGL
— Stock Scan (@stockscan01) July 17, 2024
🚨 RDGL
💰 0,18365
📈Outstanding Shares Updated:
🔴Old: 417.064.051 (2024-07-16)
🟢New: 417.564.051 (2024-07-17)
Difference: +0.1199% (+500.000)
Graph: https://t.co/ivJ5WgAFn8
Agreed MC73.
I don't think there will be a big sell off after approval. I think a lot of old longs are trapped waiting for approval. Many, myself included wanted to unload some on a IDE Submittal pop. Now that I am forced to hold and wait for approval, there is no way I sell after approval. Upon approval we will be waiting for Phase 1 results. I am 99.9999% positive of positive results. IDE Approval is the only road block in front of us at this time imo.
🚨 $RDGL ┆ OTCQB ┆ 💰 $0.1825
— OTCM Tracker (@OTCMTracker) July 10, 2024
🔑 AS:950.00M ┆ OS:418.16M ┆ R:53.45M ┆ UR:364.71M ┆ DTC:361.39M
✨ Outstanding Shares Updated:
- 🔴 From: 417,860,992 (417.86M - 7/1/2024)
- 🟢 To: 418,156,298 (418.16M - 7/9/2024)
(Diff: 295.31K, % Change: 0.0....👇https://t.co/q0x5oUhwpV
Not in AI yet...
Obviously, NVDA looks like an easy long term.
I like PLTR, probably throw some profits there and IGPT to ease into the waters...
I didn't mean to stand on a soapbox
$RDGL. On track. https://t.co/tAK7tjYKxP
— Bill Zonios (@BillZonios) June 27, 2024
I try not to get involved in the childish banter (slapping).
I don't tell the less formulated to f off, or the over exuberant to tone it down...
I'm long, very comfortable with my holdings, and extremely excited to the prospect of where we will be by year's end.
Just try to post straight and truths.
Good luck
YUP
I know exactly where it came from....😉
6 Million Shares added.
https://www.otcmarkets.com/stock/RDGL/security
Share Structure
Market Cap Market Cap
91,116,592
06/25/2024
Authorized Shares
950,000,000
06/26/2024
Outstanding Shares
416,668,239
06/26/2024
$RDGL There's 2 recent patent applications by Novartis that reference Radiogel as an option for radionuclide therapy. pic.twitter.com/01Dwmmgb0K
— Alfred Terrano (@AlfredTerrano) June 25, 2024
Felix Y. Feng
https://urology.ucsf.edu/people/felix-y-feng
Stock and Other Ownership Interests: Artera
Consulting or Advisory Role: Janssen Biotech, Astellas Pharma, SerImmune, Foundation Medicine, Exact Sciences, Bristol Myers Squibb, Varian Medical Systems, Novartis, Roivant, Bayer, BlueStar Genomics, Myovant Sciences, Tempus, Artera
Research Funding: Zenith Epigenetics
Howard M. Sandler
Stock and Other Ownership Interests: Radiogel
Consulting or Advisory Role: Janssen
Other Relationship: Caribou Publishing
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902004/
Concluded what???
I posted a direct tweet from the company.
Want to know the latest news on #RadioGel? Important updates and press releases can be emailed directly to your inbox if you subscribe on our website! #CancerAwareness #CancerTreatment #VivosIncUSA pic.twitter.com/xTaOo86H6d
— RadioGel™ (@RadioGel) June 25, 2024
Prepare to BLOW 😝
What is your real world price prediction?
I'm thinking $0.60 range is realistic...
If it doesn't happen tomorrow, I guess the question becomes:
Week 3 of June?
or
Week 4 of June?
Benzinga
https://www.benzinga.com/trading-ideas/long-ideas/24/06/39180582/alset-and-2-other-stocks-under-2-insiders-are-buying
The Dow Jones index closed higher by over 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.
Vivos
The Trade: Vivos Inc.
RDGL
CEO and President Michael K Korenko bought a total of 50,000 shares at an average price of $0.17. To acquire these shares, it cost around $8,435.
What's Happening: The company's stock fell around 16% over the past month.
What Vivos Does: Vivos Inc is a radiation oncology medical device company.
May 2024 Vivos Inc. Monthly Report EXECUTIVE SUMMARY VIVOS INC. ? Weareinitiating the internal transformation of Vivos Inc. into two operating divisions, IsoPet® and RadioGel. Strategic Reconfiguration of the two divisions is underway. ? Thestock price increased 1% this month for a total of 141% for the year. Market cap is now $70 million. ? Vivos Inc. signed a new manufacturing and quality control contract with IsoTherapeutics RADIOGEL™- HUMANTHERAPYDIVISION ? TheIDEapplication to the FDA is on target to be submitted in Q2. ? All FDAAquestions and comments over the last 5 years have been reviewed and addressed. ? TheJohnsHopkins VX2 testing draft report is under independent data review. ? TheIUVOgenotoxicity physical testing is complete and in final analysis. ? Thehydrogel shelf-life study reports and the radiation effect of hydrogel reports are completed. ? Quality Management Documents for the IDE are in order: ? SOP–812, Monitoring of Clinical Investigations ? SOP-803, Medical Device Reporting (MDR), ? SOP-030–Design Control ? SOP-020Vivos Quality Management System ? Hydrogel Spec and Yttrium-90 Particles Specifications ? IsoTherapeutics Group Quality Agreement ? Hydrogel polymer characterization and degradation testing ? Hydrogel shelf-life study ? RiskManagement Plan ? RiskManagement Report ? QAM-001Vivos Inc Quality Assurance Manual ? SOP-070Vivos Production and Process Control ? Instructions for Use ISOPET®- ANIMAL THERAPY DIVISION ? Thereis an increase in pet patients undergoing evaluations for possible IsoPet® treatment ? Currently in discussion with potential new regional IsoPet® clinics in FL,TX, NM, NJ ? Currently looking for an exotic animal as a case study for IsoPet® ? TheUniversity of Wisconsin was certified as an IsoPet® regional clinic for equine therapy. MARKETING ? Benzinga article is being prepared and the timing of the first article is under careful consideration. ? Newtrade show banners and marketing material have been created to focus on enticing new IsoPet® regional clinics to join the IsoPet® family. ? Weareattending American College of Veterinary Internal Medicine-ACVIM Conference is June 5-8 in Minneapolis, MN and Pacific Veterinary Conference-PACVET in San Francisco, CA July 11-14 to promote IsoPet® as a safer, more effective cancer treatment.May 2024 Monthly Report Page 2 ? Blogs posted: ? May5-IsoPet® blog “10 Reasons To Become An IsoPet® Certified Veterinary Clinic” ? May14-IsoPet® blog “IsoPet and Sarcoids- Equine Skin Cancer” ? May18-IsoPet® blog “Dogs With The Highest Risk For Cancer & How You Can Help” ? May27-IsoPet® blog “The Science Behind IsoPet®- A Safer Way Of Treating Cancer in Animals” ? May27-RadioGel™ blog- “The Science of RadioGel™ A New Way Of Treating Cancer with Y-90” ? TopBlog to date is still “Top 20 Frequently Asked Questions About Cancer in Pets” this is also posted as a website page on the FAQ page on the IsoPet® website ? TheT-Shirt Contest for IsoPet® and RadioGel™ was well received and ideas will be discussed in June. ? Branded clothing arrived at head office in Kennewick for Vivos Inc., RadioGel™ and IsoPet® MANUFACTURING ? Hydrogel optimization and injection system production are being refined. ? Vivos signed a contract for our Peltier Chiller production and is currently increasing inventory. ? Bytheir request, Vivos Inc. is working with Akina, our polymer contractor, to design a general laboratory chiller for laboratory use since the capability for controlled cooling which we patented for our chiller would have general applicability. QUALITY MANAGEMENT SYSTEMDOCUMENTSREVISED ? Vivos/IsoTherapeutics Quality and Manufacturing Agreement ? QM-001R01Quality Assurance Manual ? DMR-001R01RadioGel Master Device Record ? SP-003R01RadioGel™/IsoPet® RTU Product Specification ? MRB-004Production Procedure and Batch Record– Preparation of PLGA-g-PEG Polymer TEST PLANS ? P-014Effect of Blue Dye on Hydrogel Rheology ? TR-006PLGA-g-PEG Hydrogel Shelf Life ? TR-009Y-90 PO4 PLGA-g-PEG Hydrogel Degradation Rad Effect on Hydrogel ? TR-010Test Report for the Shelf-Life Study of PLGA-g-PEG Polymer Through Freeze Thaw Cycles ? TR-013Yttrium Phosphate Particle Size After SOP Production ? TR-014Effect of Blue Dye on Hydrogel Rheology PUBLICATIONS & PRESENTATIONS ? On5/21/24 Rebecca Krimins’ abstract "Yttrium-90 hydrogel injected in an animal tumor model" has been accepted as an oral presentation, which is now included in the scientific programme at the 5th European Congress of Medical Physics (ECMP 2024) in Munich/Germany. ? On5/18/24 Darrell Fisher’s poster “Direct Interstitial Injection: An Approach to Optimizing Therapeutic Ratios for Safe and Effective Delivery of High-dose Radionuclide Therapy in Treating Solid Tumors”- Darrell R. Fisher, Versant Medical Physics and Radiation Safety; Michael K. Korenko, Vivos, Inc. was accepted at the International Radiation Protection Association (IRPA)and IRPA 16th International Congress and 69th Health Physics Society Annual Meeting- July 7-12, 2024Orlando FL.
In our efforts to keep our loyal followers up to date our May 2024 Monthly report is out with the extended version on our http://VivosInc.com website under "Monthly Reports". #VivosIncUSA #RadioGel #IsoPet #CancerTreatment $RDGL
True
But they now have the BDD in hand.
Logic supports your numbers, but I also know when it comes to the market, especially the OTC... Who the fk knows?
I am 100% confident we are in the dollars in 18 months either way
Here's the text
@ToddAnalytics
Bill, you and the crew continue supporting us at @QueTraders and I cannot find words to suffice our appreciation.
Updated podcasts coming soon with video, so be prepared to deal with my ugly mug moving forward. Intend to get you to join on an episode thereafter.
$RDGL to the moon, baby!
4:43 PM · May 30, 2024 104 Views
NICE TWEET! by @QueTraders
Bill, you and the crew continue supporting us at @QueTraders and I cannot find words to suffice our appreciation.
— Todd Analytics (@ToddAnalytics) May 30, 2024
Updated podcasts coming soon with video, so be prepared to deal with my ugly mug moving forward. Intend to get you to join on an episode thereafter. $RDGL to the…
Great post!
That sums up, where we are!
RDGL, dollars coming!
I agree with the Big Pharma narrative.
They don't want to cure cancer, but this is an effective treatment that keeps the wheel turning....
I can see Big Pharma paying for this treatment to extend lives, without the fear that it is a "cure".
They will put this in their greedy quiver to keep making money.
Good , news is consequently, it will extend lives.
The extension of life means more money for countries that can afford the treatment and keep the wheel turning.
I actually think they want this to succeed! (Me too!)
Amazing!!!
Also, "After the second Indication for Use, we intend to apply for a broad Indication for Use which we would target to obtain approval to treat all solid tumors."
Website is up
radiogelusa.com
$RDGL radiogelUSA.com
now say "New Site Launching May 1st" also they have aa active MESSAGE button in the lower right corner...
New website will be here:
https://radiogelusa.com/
Launches May 1st.
There was a large surge of volume and price increase at the last close.
On a Friday...
In the OTC...
Look for continuation in share price rise.
IMO
Catfish
What's your X handle?
Or message me
I can't answer Private Messages
The answer is yes